UG1CA286954

NCI CANCER SCREENING RESEARCH NETWORK: COORDINATING AND COMMUNICATION CENTER - SUMMARY/ABSTRACT

The promise of early detection to reduce the burden of cancer is an easily understood and highly desired intervention point in the cancer continuum. Recent developments of multicancer detection (MCD) technologies have fueled already strong interest in their use, well in advance of compelling data describing the impact of MCD-based screening on cancer mortality.

In addition to limited data available on sensitivity and lead time to assess these MCD tests, the complexities of implementing them in a real-world clinical environment require careful evaluation to assess the frequency of achieving resolution of a positive MCD test (i.e., a specific cancer diagnosis), the nature, timeline and cost of those procedures, and the potential to increase cancer worry and health inequities.

To help to address these critical caps in data, the Cancer Screening Research Network (CSRN) will be a cooperative group structure with the expertise, infrastructure and access to appropriate patient populations needed to provide high quality evidence on the value of MCD tests in real-world settings.

The goal for the vanguard phase is to design and conduct a randomized controlled feasibility trial of two promising MCD tests. The CSRN Communication and Coordinating Center (CCC) in conjunction with the CSRN Statistics and Data Management Center (SDMC) and the NCI will lead and support this critical national effort.

Our specific objectives are to: (1) provide exceptional scientific and clinical expertise in the design and implementation of multicenter cancer screening trials, and particularly randomized trials evaluating MCD assays. (2) develop the organizational structure and administrative relationships to assure CSRN success. (3) develop and maintain effective communication channels and materials to promote CSRN success. (4) support CSRN access sites in their recruitment and retention efforts.

By these efforts, the CSRN will assess the feasibility of and establish the core infrastructure needed to conduct future full-scale trials of MCD tests and other cancer screening studies. Through the efforts of the vanguard phase, the CSRN will create the infrastructure, data and learnings needed to support full-scale trials and additional observational studies of the most promising MCD tests and other cancer screening approaches.

Fred Hutchinson Cancer Center

TO REDUCE CANCER RISK, INCIDENCE, MORBIDITY, AND MORTALITY AND ENHANCE QUALITY OF LIFE IN CANCER SURVIVORS THROUGH AN ORDERLY SEQUENCE FROM RESEARCH ON INTERVENTIONS AND THEIR IMPACT IN DEFINED POPULATIONS TO THE BROAD, SYSTEMATIC APPLICATION OF THE RESEARCH RESULTS THROUGH DISSEMINATION AND DIFFUSION STRATEGIES. PRIMARY EMPHASIS IS ON THE INCLUSION OF CANCER PREVENTION AND CONTROL INTERVENTION(S) IN ANY PROPOSED STUDY. CANCER PREVENTION AND CANCER CONTROL RESEARCH STUDIES ARE CLASSIFIED INTO ONE OF FIVE PHASES: (1) HYPOTHESIS DEVELOPMENT, (2) METHODS DEVELOPMENT AND TESTING, (3) CONTROLLED INTERVENTION TRIALS TO ESTABLISH CAUSE-AND-EFFECT RELATIONSHIPS, (4) RESEARCH IN DEFINED POPULATIONS, AND (5) DEMONSTRATION AND IMPLEMENTATION STUDIES. PRIMARY INTERESTS ARE IN RESEARCH ON CANCER CONTROL INTERVENTIONS IN PHASES 2 THROUGH 5, AND ON CANCER PREVENTION RESEARCH IN ALL PHASES. CANCER PREVENTION AND CONTROL PROGRAMS INCLUDE THOSE IN THE FOLLOWING AREAS: (1) CANCER EPIDEMIOLOGY, (2) CANCER COMMUNICATIONS, (3) NUTRITION, DIET, AND PHYSICAL ACTIVITY, (4) SCREENING AND EARLY DETECTION IN HEALTH CARE DELIVERY, (5) BIOBEHAVIORAL MECHANISMS, (6) TOBACCO CONTROL, (7) HEALTH DISPARITIES RESEARCH, (8) SUPPORTIVE CARE AND SURVIVORSHIP, (9) HEALTH SERVICES AND OUTCOMES RESEARCH, AND (10) SURVEILLANCE RESEARCH. CANCER CONTROL USES SMALL BUSINESS INNOVATION RESEARCH (SBIR) AND SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAMS TO ENGAGE DOMESTIC SMALL BUSINESS CONCERNS IN FEDERAL RESEARCH AND DEVELOPMENT THAT HAS POTENTIAL FOR COMMERCIALIZATION. THE GOALS OF THE SBIR & STTR PROGRAMS ARE TO STIMULATE TECHNOLOGICAL INNOVATION, INCREASE PRIVATE-SECTOR COMMERCIALIZATION OF FEDERAL RESEARCH AND DEVELOPMENT, INCREASE SMALL BUSINESS PARTICIPATION IN FEDERALLY FUNDED RESEARCH AND DEVELOPMENT, AND FOSTER PARTICIPATION BY SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. THE STTR PROGRAM REQUIRES THE SMALL BUSINESS CONCERN TO FORMALLY COLLABORATE WITH A RESEARCH INSTITUTION IN PHASE I AND PHASE II OF THE PROGRAM.

93.353 - 21st Century Cures Act - Beau Biden Cancer Moonshot

National Cancer Institute (NCI) [HHS - NIH]

Washington United States

State-Wide

NCI Cancer Screening Research Network: Coordinating and Communication Center (UG1 Clinical Trial Required) (RFA-CA-23-022)

Amendment Since initial award the total obligations have increased 543% from $1,125,001 to $7,230,152.